Ambrx Biopharma Price to Free Cash Flow Ratio 2020-2022 | AMAM
Historical price to free cash flow ratio values for Ambrx Biopharma (AMAM) since 2020.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Ambrx Biopharma Price to Free Cash Flow Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM FCF per Share | Price to FCF Ratio |
| 2023-01-31 | 1.89 | inf | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Biomedical and Genetics | $0.078B | $0.007B |
| Ambrx Biopharma Inc. is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. Ambrx Biopharma Inc. is based in SAN DIEGO. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bristol Myers Squibb (BMY) | United States | $153.147B | 9.34 |
| GSK (GSK) | United Kingdom | $71.894B | 8.95 |
| Bio-Rad Laboratories (BIO.B) | United States | $12.069B | 28.64 |
| QIAGEN (QGEN) | Netherlands | $11.086B | 18.92 |
| Ginkgo Bioworks Holdings (DNA) | United States | $3.531B | 0.00 |
| Myovant Sciences (MYOV) | United Kingdom | $2.613B | 0.00 |
| Arcus Biosciences (RCUS) | United States | $1.618B | 24.29 |
| Biohaven (BHVN) | United States | $1.266B | 0.00 |
| Emergent Biosolutions (EBS) | United States | $0.645B | 5.07 |
| ADC Therapeutics SA (ADCT) | Switzerland | $0.378B | 0.00 |
| Enzo Biochem (ENZ) | United States | $0.067B | 0.00 |
| SQZ Biotechnologies (SQZ) | United States | $0.024B | 0.00 |
| Gelesis Holdings (GLS) | United States | $0.022B | 0.00 |
